Israel reopens its dumping probe into Canadian cannabis
Growers want a temporary levy as soon as possible • Importers call it a false cry of foul

The Ministry of Economy has officially announced the reopening of the anti-dumping investigation into imports of medical cannabis from Canada. The notice was published a few hours after Cannabis Magazine first reported it, and after the ministry had at first refused to confirm that a letter to Canada existed. The official notice now publishes, for the first time, details of the full complaint behind the investigation, including material that did not appear in the previous round: a named list of 18 Israeli companies that collapsed, a new line of argument about government subsidies in Canada, and import figures pointing to a 42% jump in a single year.
The complaint was filed on 30 July by the cultivation companies Trichome and Evergreen, through the law firm Weiss, Porat & Co.: lawyer Ze'ev Weiss and Prof. Arye Reich, among Israel's leading experts in international trade law. The public version of the complaint, circulated to interested parties, is partly blacked out for commercial secrets, but what remains visible draws a detailed picture.
The main demand: a temporary guarantee, immediately, at the full rate
On the first page of the complaint is the demand that confirms what people in the industry had already estimated: the complainants ask «to impose as soon as possible a temporary guarantee in order to give temporary protection to the producing industry in Israel… according to the full dumping margin that will be found in the preliminary decision».
As Cannabis Magazine has reported, a temporary guarantee, unlike a permanent levy, is imposed by a decision of the commissioner of trade levies himself, without the approval of the finance minister, whose veto buried the levy in the previous round. Under the timetable set in the opening decision, such a guarantee could be imposed as early as the beginning of October, shortly before the then-upcoming Knesset elections.
The complainants also frame it as an emergency: «This is in fact the last opportunity to save a producing industry that is important to Israel's economy, and important to its security and to the welfare of the patients who need relief.»
The collapse list: 18 companies, name by name
For the first time the complaint includes a named and dated list of companies that stopped production activity since the first investigation. Among them: Tikun Olam, one of the industry's pioneers, which closed its production plant in March 2025 and was left with a «no-contact» licence only; Bazelet Pharma, which applied to the court for a stay of proceedings; David and Goliath, whose employees applied to the court in November 2025 in an urgent bid to open insolvency proceedings; Talcan, against which an insolvency file was opened in 2025; Can Pharmaceutica (the Better brand), whose business licences were cancelled in 2024; and also BOL Pharma, Panaxia, Pharmocann, Univo, Cannasure, Plantis, Intlikana, Cannaerva and others.
The import side reads the same list very differently. First, it is argued that some of the companies on the list closed not because of imports but because of regulatory breaches, police decisions or criminal suspicions. Second, some of them were themselves importers: BOL Pharma, for example, was among the largest importers in the industry. In the case of Tikun Olam a particularly odd situation arises: in the complaint it appears as an example of the collapse of local production, while in the commissioner's own decision, published in the same bundle of documents, it appears on the list of active importers.
The picture is also not one-directional. Alongside the collapses, new cultivation facilities have been opened and expanded in recent years: Plantc's facility was expanded, Ganja Geek's new indoor facility was built, a new indoor facility was opened in the Dead Sea area, and Trichome itself invested in expanding its facility and increased its activity.
At Trichome, the main complainant, they reject that reading of the list. «It is true that some companies closed for various regulatory reasons, but many players in the industry ran into significant financial difficulties against the background of unfair competition. That is exactly one of the issues the investigation is meant to examine,» Trichome CEO Tony Levy told Cannabis Magazine. «Even someone who is putting up a new facility today, after an enormous investment, is struggling with the state of the market.»
A new front: Canadian subsidies
The newest and most prominent argument in the complaint concerns government subsidies in Canada. The complainants argue that Canadian cannabis producers enjoy government support, federal, provincial and local, amounting cumulatively to hundreds of millions of dollars, and that some of the programmes are explicitly aimed at encouraging exports.
The complaint cites examples from official Canadian government publications: PBG Biopharma received a grant of 5.39 million Canadian dollars, with an expected result of «increased exports»; Organigram received about 793,000 dollars; Tilray about 323,000 dollars. It also quotes a report in the trade journal MJBizDaily that since 2018 Canadian cannabis companies received about 32.8 million dollars from federal support programmes, and more than 140 million dollars more during the COVID period. It should be noted that Organigram and Tilray, which are mentioned in the complaint, have not exported to Israel for a long time: Organigram for at least about a year, and Tilray for more than two years.
The figure at the heart of the complaint: imports accelerate from quarter to quarter
The complaint presents data from publications of the Israel Medical Cannabis Agency (IMCA, the medical cannabis unit at the Ministry of Health) showing that imports jumped from about 21.5 tons in 2024 to about 30.5 tons in 2025, a rise of about 42% in one year, with a 128% jump in the third quarter of 2025 compared with the same quarter a year earlier. Those figures are consistent with customs data in the commissioner's decision, which showed a 33% rise in the monetary value of imports between 2023 and 2025. More recent figures, through May 2026, present a mixed picture: in the first months of 2026 there was some slowdown in imports, but in May 2026 about 3.5 tons were imported, above the monthly average for 2025.
Quarter by quarter, as presented in the complaint (2024 vs 2025): Q1 5.7 to 7.4 tons (+29%); Q2 5.3 to 5.7 tons (+9%); Q3 3.6 to 8.3 tons (+128%); Q4 6.8 to 9.1 tons (+34%). Source: IMCA publications, as presented in the dumping complaint (graphics: Cannabis Magazine).
On the import side they also reject the subsidies front. «I am not familiar with government subsidies there, and besides, facilities have closed there too, and there are difficulties in that market too,» a senior figure in the industry who asked not to be named, one of the prominent importers, told Cannabis Magazine. It is also argued that the import process into Israel has been tightened significantly of late: the Canadian product is required to meet the Israeli cultivation standard, meaning it is grown specifically for the Israeli market. That, in his account, contradicts the narrative of «Canadian surpluses dumped on Israel», because the Canadian producer has no interest in moving such goods into his own domestic market.
The legal meaning of the subsidies argument goes beyond general background: the complainants demand that, because of the «distortion» the subsidies create in Canadian market prices, the «normal price» in Canada should be calculated not according to actual market prices but according to production costs plus a reasonable profit (a «constructed price»), a method that could lead to a dumping margin even higher than the 125% now claimed.
The background to Israeli growers' dumping claims can also be found on pharmacy shelves: a series of products from Canada is now sold to the consumer at only about 90–100 shekels for a 10-gram pack, while according to people in the growing industry the price to pharmacies is about 30–40 shekels, leaving the Canadian producer, they argue, only about one shekel per gram, a price that does not even cover production costs. It should be stressed that a low price in itself does not prove dumping. The legal test is a comparison between the export price and the price in the Canadian market, and these claims are exactly what the investigation is meant to examine.
«Special relationships»: the claims against Cronos and Kantek
The complaint raises another argument: some of the imports into Israel are carried out between related parties, and therefore their prices do not reflect a «normal course of business». According to the complaint, Cronos Israel imports products from its parent company in Canada, the Cronos group, and the company Kantek has its own farm in Canada from which it imports to Israel.
On the import side the reply is that purchasing from a parent company is a legitimate business practice, and that the fact that a related company receives a lower price than an outside buyer would pay does not necessarily show that the price is below the price in the Canadian market, which is the relevant comparison for examining whether dumping exists.
«A false cry of foul»: the import side rejects the complaint entirely
A senior figure on the import side, familiar with the details of the proceeding, told Cannabis Magazine that the central question is whether there is a «market failure» at all that justifies intervention. «The main complainant, Trichome, is the most profitable company in the field. The information is public: its controlling shareholder is a public company. They are profitable year after year and they recouped the investment. When the complainant is the most profitable company in the field, that already proves there is no market failure.» Trichome is indeed now considered one of the most successful and profitable companies in Israel's cannabis industry, though according to people in the industry its profits too have been on a downward trend in recent years, a trend that the growing side attributes in part to imports.
«Growing and marketing cannabis is a profession, a field with knowledge,» the source added. «Companies that closed maybe gambled, dreamed dreams, and saw that it is not easy. Look, Trichome know how to work and they succeed. I take my hat off to them, they put up good numbers. But competing with us like this is not fair, it is below the belt: a false cry of foul.»
The source also recalled that the large importers are not only importers: «We import a lot, but we also have farms in Israel. It looks exactly the opposite: someone here is trying to harm competition, in order to earn more. In the end the ones who will be hurt are companies that have no local growing, and of course the patients, because the price will rise, and not only of imported goods. Local growing will also raise prices and earn more.»
As for what comes next, his assessment was unequivocal: «I do not believe a permanent levy will be imposed. The commissioner is going full force for the temporary model: that he will do. But when it has to pass objective tests in order to become permanent, like the budget department at the Finance Ministry, I estimate that will not happen. It is not by chance that the finance minister imposed a veto last time, and the Competition Authority already examined the market-failure question thoroughly. I estimate the commissioner will simply drag the process on for years, in a 'temporary' state, and prices will rise significantly for patients.» In his assessment, this proceeding too will end up as a petition to the court.
It should be noted in this context that the test fixed in the law for a dumping investigation is not «market failure», but three cumulative conditions: the existence of dumped imports, material injury to the domestic producing industry, and a causal link between them. The broader «market failure» question stood at the centre of the finance minister's veto in the previous round, but it is relevant to the political decision on a permanent levy, not to the investigation itself and not to the commissioner's authority to impose a temporary guarantee.
Trichome: «If there is no dumping, present the data to the commissioner»
Trichome rejects the rest of the claims. «The most important thing is to be clear that we are not against imports and not against competition. On the contrary, we are in favour of fair and lawful trade,» Levy told Cannabis Magazine. «If the importers believe there is no dumped import, they should present the data to the commissioner. That is exactly what the proceeding is for. The commissioner will examine the issues and make a professional decision according to the law. Why are courts, petitions, lobbyists and campaigns that cost millions needed?»
In his account, the levy, if it is imposed, is much more targeted than it is made to appear: «As I understand it, if a levy is imposed, it will apply according to the findings of the investigation and to whoever is found to have carried out dumped imports. So the claim that all cannabis prices will rise across the board is not correct.» It should be noted that in the previous round differential rates were in fact set by company (from 12% up to 165%), but the maximum rate was applied by default to every Canadian company that did not cooperate with the investigation. The actual scope therefore depends on how far Canadian producers cooperate.
Asked how a profitable company claims injury from dumping, Levy replied: «What is the problem with us being profitable? That shows we are run properly. But the discussion is not about this or that company. It is about the future of the local industry, about its ability to go on existing in Israel, and about the ability of Israeli producers to compete on fair trade terms. Why should we have to rely on Canadian output, when Canada completely prohibits any commercial import of cannabis into its territory, not from Israel and not from anywhere else?»
Levy also said: «We filed the complaint and we stand behind it, because we believe there is great importance in protecting Israeli industry and in maintaining fair competition. But we are not alone: we are members of the Manufacturers Association and we act as part of the commitment to strengthen local industry, to keep fair conditions of competition, and to ensure a stable supply for patients.» Unlike Trichome, he said, other, smaller companies in Israel were afraid to identify publicly with the complaint, because some of the large-volume importers also buy output from those small local farms, and anyone who identifies as supporting the complaint could lose purchase contracts.
Levy also points to the regulatory asymmetry with Canada, which completely prohibits commercial cannabis imports into its territory: «Canadian companies once tried to set up growing facilities in Colombia in order to grow cheaply and import from there. Canada saw that and stopped it, and those companies lost a fortune. That is how a country protects its industry. Why not in Israel?» An Israeli exporter, he added, is required to commit that the product it exports will remain available to the local market alongside the export, while an importer into Israel is not required to make a parallel commitment of supply continuity for the imported product, so the market is flooded with different cultivars in small batches and without therapeutic continuity.
And what about the patients?
As at every stage of the saga, the central question for about 140,000 medical-cannabis patients in Israel is the question of price. Importers and opponents of the levy have warned in the past that a levy would lead to a sharp rise in the prices of imported products, and that more expensive Canadian cannabis could also pull up the prices of Israeli output and of the whole market.
In the previous round, by contrast, the Ministry of Economy pointed to a written commitment by local producers not to raise prices if a levy were imposed, alongside a proposed price-control mechanism. Commissioner Danny Tal also estimated then that full use of local production capacity, which in his account was then operating at about half of capacity, would lower the production cost per gram and might even allow Israeli output to become cheaper.
It should also be remembered that the price range in the Israeli market is now very wide, including within imports themselves, which sell from about 100 shekels a pack up to about 500 shekels in premium categories, and also includes Israeli output sold at especially low prices. The actual effect on a patient's shopping basket therefore depends on the mix of products, the category and the players' pricing policy, and will become clear only if and when measures are actually imposed.
The timetable: everything before the elections?
Under the opening decision, the parties, producers, importers, Canadian exporters and the Ministry of Health, were to submit their answers to the questionnaires by 7 September 2026. A preliminary decision was expected within 60 to 90 days, that is between early October and early November, with temporary measures possible under the law from 60 days after the opening. General elections were planned for the end of October.
In the opening decision the commissioner also included an explicit warning: failure to cooperate with the investigation could lead to findings being set on the basis of «the best information available», the rule that in the previous round led to dumping margins of hundreds of percent being set for companies that did not answer the questionnaires.